(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Brand names,
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Analogs
- (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate
- (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid
- (5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
- 5,8,11,14,17-Icosapentaenoic acid
- Eicosapentaenoic acid
- EPA
- Eicosapentaenoic
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Brand Names Mixture
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Chemical_Formula
C20H30O2
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
RX_link
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
fda sheet
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
msds (material safety sheet)
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Synthesis Reference
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Molecular Weight
302.456 g/mol
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Melting Point
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
H2O Solubility
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
State
Oily Liquid
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
LogP
6.23 +/- 0.48
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Dosage Forms
Capsule (usually in fish oil in a combination with DHA)
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Indication
EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Pharmacology
Eicosanoids are chemical messengers derived from 20-carbon polyunsaturated fatty acids that play critical roles in immune and inflammatory responses. Both 20-carbon omega-6 fatty acids (arachidonic acid) and 20-carbon omega-3 fatty acids (EPA) can be found in cell membranes. During an inflammatory response, arachidonic acid and EPA are metabolized by enzymes known as cyclooxygenases and lipoxygenases to form eicosanoids. Increasing omega-3 fatty acid intake increases the EPA content of cell membranes and decreases the arachidonic acid content, resulting in higher proportions of eicosanoids derived from EPA. Physiologic responses to arachidonic acid-derived eicosanoids differ from responses to EPA-derived eicosanoids. In general, eicosanoids derived from EPA are less potent inducers of inflammation, blood vessel constriction, and clotting than eicosanoids derived from arachidonic acid.
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Absorption
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
side effects and Toxicity
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Patient Information
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
Organisms Affected
No information avaliable